Hodgkin lymphoma - Nursing Case Study

Pathophysiology

• Primary mechanism: Hodgkin lymphoma originates from the malignant transformation of B lymphocytes, leading to the formation of Reed-Sternberg cells, which are large, abnormal cells that are a hallmark of the disease and contribute to its progression.

• Secondary mechanism: The presence of Reed-Sternberg cells in lymphoid tissues results in the secretion of cytokines, causing an inflammatory response and attracting other immune cells, which further supports the growth and survival of these malignant cells.

• Key complication: The accumulation of Reed-Sternberg cells and the associated inflammatory response can cause lymph node enlargement, systemic symptoms such as fever and weight loss, and, if untreated, can spread to other organs, compromising their function.

Patient Profile

Demographics:

32-year-old male, office manager

History:

• Key past medical history: Previously healthy, no significant medical history

• Current medications: None reported

• Allergies: Penicillin

Current Presentation:

• Chief complaint: Persistent fatigue and unexplained weight loss

• Key symptoms: Enlarged lymph nodes in the neck and armpits, night sweats, intermittent fever, itchy skin

• Vital signs: Blood pressure 130/85 mmHg, heart rate 100 bpm, respiratory rate 20 breaths per minute, temperature 38.2°C (100.8°F)

Section 1

Following the initial assessment and diagnosis of Hodgkin lymphoma, the patient underwent a series of diagnostic tests, including a biopsy of the enlarged lymph nodes and imaging studies to establish the extent of disease involvement. The biopsy confirmed the presence of Reed-Sternberg cells, characteristic of Hodgkin lymphoma, and staging scans indicated involvement of lymph nodes above and below the diaphragm, classifying the disease as stage III. Blood tests revealed anemia, with a hemoglobin level of 10.5 g/dL, and an elevated lactate dehydrogenase (LDH) level at 250 U/L, suggesting increased cellular turnover and systemic involvement.

As treatment commenced with ABVD chemotherapy (Adriamycin, Bleomycin, Vinblastine, and Dacarbazine), the patient initially tolerated the regimen well. However, after the second cycle of chemotherapy, he developed febrile neutropenia, indicated by a sudden spike in temperature to 39.0°C (102.2°F) and an absolute neutrophil count of 450 cells/mm³, placing him at high risk for infections. Despite the administration of broad-spectrum antibiotics and supportive care, the patient reported increasing shortness of breath and chest discomfort, prompting further investigation.

A chest X-ray revealed new bilateral pulmonary infiltrates, raising concerns for a potential opportunistic infection or Bleomycin-induced pulmonary toxicity. Given the clinical scenario, the healthcare team faced a critical decision: whether to continue with the current chemotherapy regimen or modify it to reduce the risk of further pulmonary complications. This situation required careful clinical reasoning, weighing the risks of disease progression against the potential harm from chemotherapy-related adverse effects. The next step in the patient's journey involved a multidisciplinary team approach to optimize treatment strategy, monitor for additional complications, and manage the existing ones effectively.

Section 2

Following the identification of febrile neutropenia and new bilateral pulmonary infiltrates, the healthcare team decided to prioritize further diagnostic evaluations to better understand the underlying cause of the patient's respiratory symptoms. High-resolution computed tomography (HRCT) of the chest was performed, revealing diffuse ground-glass opacities, consistent with interstitial lung disease. These findings raised the suspicion of Bleomycin-induced pulmonary toxicity, a known complication of the chemotherapy regimen. Given the critical nature of this potential complication, a bronchoscopy with bronchoalveolar lavage was conducted to rule out infectious causes. The lavage results were negative for bacterial, viral, and fungal pathogens, supporting the likelihood of drug-induced toxicity.

In light of these new diagnostic results, the multidisciplinary team, including oncologists, pulmonologists, and pharmacists, convened to discuss the best course of action. The team decided to temporarily discontinue Bleomycin from the chemotherapy regimen to prevent further pulmonary damage while continuing the other agents. Additionally, the patient was started on corticosteroids to manage the inflammatory response associated with the suspected Bleomycin toxicity. The patient's oxygen saturation was closely monitored, and supplemental oxygen was provided to maintain adequate levels.

Over the following week, the patient's respiratory status showed gradual improvement, with a reduction in shortness of breath and chest discomfort. Repeat HRCT demonstrated a partial resolution of the ground-glass opacities. However, the team remained vigilant for additional complications, recognizing the ongoing risk of infection due to the patient's neutropenic state. This development underscored the importance of balancing effective lymphoma treatment with the management of treatment-related adverse effects, setting the stage for further adjustments to the patient's therapeutic regimen as needed.

Section 3

New Complications

Despite the initial improvement in the patient's respiratory status, a new complication emerged. The patient began experiencing increasing fatigue, palpitations, and mild dizziness. During a routine assessment, the nurse noted that the patient's heart rate was elevated at 110 beats per minute, and blood pressure was slightly low at 95/60 mmHg. An electrocardiogram (ECG) was performed, revealing sinus tachycardia with occasional premature ventricular contractions. These findings, combined with the patient's symptoms, prompted the healthcare team to investigate potential cardiac issues, given the known cardiotoxic potential of some chemotherapy agents.

The team decided to conduct an echocardiogram, which revealed a mildly reduced left ventricular ejection fraction of 45%, suggesting early signs of chemotherapy-induced cardiomyopathy. This development required careful consideration of the patient's current treatment plan, as the benefits of continuing the chemotherapy regimen needed to be weighed against the risk of further cardiac damage. The oncology team consulted with a cardiologist to develop an adjusted treatment strategy that would address the newly identified cardiac complications while continuing to manage the lymphoma effectively.

In response to these findings, the decision was made to initiate a low-dose beta-blocker to manage the patient's heart rate and support cardiac function. Additionally, the patient's fluid status was closely monitored to prevent any exacerbation of cardiac symptoms. The multidisciplinary team considered modifying the chemotherapy regimen to reduce potential cardiac stress, emphasizing the importance of an individualized approach to cancer treatment that addresses both the malignancy and the associated treatment-related adverse effects. This careful balance aimed to optimize the patient's overall health and treatment outcomes, setting the stage for further monitoring and adjustments as necessary.

Section 4

As the patient continued with the modified treatment plan, the healthcare team closely monitored for any changes in the patient's condition. Within two weeks, the patient reported a slight improvement in their energy levels and a reduction in palpitations. However, the nurse noted during a routine check-up that the patient appeared unusually pale and exhibited mild dyspnea upon exertion. Vital signs indicated a heart rate of 100 beats per minute, blood pressure of 100/65 mmHg, and a respiratory rate of 22 breaths per minute. Given the new symptoms, the oncology team decided to conduct a complete blood count (CBC) to assess for any hematological complications potentially linked to the chemotherapy regimen or the patient's underlying condition.

The CBC results revealed a significant drop in hemoglobin levels to 8.5 g/dL, with accompanying mild leukopenia and thrombocytopenia. These findings suggested the development of chemotherapy-induced myelosuppression, posing a new challenge in the management of the patient's lymphoma. The patient's anemia likely contributed to their fatigue and dyspnea, necessitating immediate intervention. The team decided to initiate erythropoiesis-stimulating agents (ESAs) to address the anemia and planned for a potential blood transfusion if the patient's symptoms did not improve.

Recognizing the complexity of the patient's condition, the healthcare team considered additional supportive measures, such as dietary modifications and iron supplementation, to support hematopoiesis. The patient's fluid status continued to be monitored closely, given the ongoing cardiac concerns. This new complication highlighted the importance of a comprehensive and dynamic approach to care, with an emphasis on balancing effective cancer treatment with the management of adverse effects to optimize the patient's quality of life and treatment outcomes. The team was prepared to reassess and adjust the treatment plan as necessary, ensuring a proactive response to any further developments in the patient's condition.

Section 5

As the patient began receiving erythropoiesis-stimulating agents, the healthcare team closely monitored their response to the intervention. Over the next week, the patient reported a mild improvement in energy levels, but the episodes of dyspnea persisted, particularly during physical activities. During a follow-up visit, the nurse noted that the patient's pallor remained unchanged, and they continued to exhibit exertional dyspnea. A repeat CBC showed a slight increase in hemoglobin to 9.1 g/dL but continued mild leukopenia and thrombocytopenia, suggesting partial response to the ESAs with ongoing myelosuppression.

The patient's vital signs were relatively stable, with a heart rate of 95 beats per minute, blood pressure of 105/68 mmHg, and respiratory rate of 20 breaths per minute. However, the persistence of symptoms prompted the team to consider additional diagnostic evaluations to rule out other potential causes of dyspnea, such as cardiopulmonary complications or occult bleeding. A chest X-ray and echocardiogram were ordered to assess cardiac function and pulmonary status, given the concern for potential fluid overload or cardiac involvement related to the lymphoma.

The results of the imaging studies revealed mild pleural effusion but no significant cardiomegaly or pulmonary edema. The oncology team discussed the possibility of the pleural effusion being related to the lymphoma itself or as a complication of treatment. Consequently, a thoracentesis was planned to relieve symptoms and analyze the pleural fluid for cytological examination. This step was crucial to determine the underlying cause of the effusion, ensuring that the treatment strategy could be adjusted appropriately to address both the lymphoma and its complications effectively. The team remained vigilant, prepared to modify the treatment plan based on the evolving clinical picture and the patient's response to interventions.